Quantcast

Latest Antivirals Stories

2014-07-15 12:28:37

Unprecedented Growth Will be Fuelled by Rapid Uptake of All-Oral, Interferon-Free Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., July 15, 2014 /PRNewswire/ -- Decision Resources Group finds that the hepatitis C virus (HCV) population is large with more than 2 million diagnosed, chronically infected cases throughout the G7 markets (United States, France, Germany, Italy, Spain, United Kingdom and Japan). Many of these patients, including more than 270,000 with...

2014-06-28 13:57:32

TUM Virus infection supports organ acceptance Chronic hepatitis C virus infections are among the most common reasons for liver transplants. Because existing viruses also infect the new liver, the immune system is highly active there. Despite this, the new organ is not rejected, as scientists from the Helmholtz Zentrum München and the Technische Universität München (TUM) have now discovered. The long-term stimulation of the innate immune system by the virus actually increases the...

2014-06-18 12:29:54

Arrival of IFN-Free Therapies Will Bring Patients For Whom Current Therapies are Ineffective Back to the Drug-Treated Population, According to Findings from Decision Resources Group BURLINGTON, Mass., June 18, 2014 /PRNewswire/ -- Decision Resources Group finds that China's market for hepatitis C virus (HCV) drugs will be driven by an increase in its drug-treated population, following the introduction of novel HCV therapies. Nearly a third of patients diagnosed with HCV do not receive the...

2014-06-17 04:21:28

NORTH CHICAGO, Ill., June 17, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the Marketing Authorization Applications (MAAs) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection have been validated and are under accelerated assessment by the European Medicines Agency (EMA). Accelerated assessment, which is designated to new medicines of major public health...

2014-06-16 23:04:46

GIA announces the release of a comprehensive global report on Growth Factors (Blood and Tissue) markets. Global market for Growth Factors (Blood and Tissue) is forecast to reach US$48 billion by 2020, driven by growing demand for effective, cost-efficient therapeutics, and increasing significance of growth factors in the treatment of chemotherapy-associated anemia and neutropenia. San Jose, California (PRWEB) June 16, 2014 Follow us on LinkedIn – Fuelled by the growing importance of...

2014-06-13 16:23:26

NORTH CHICAGO, Ill., June 13, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the New Drug Application (NDA) for its investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection has been accepted by the U.S. Food and Drug Administration (FDA) and has been granted priority review. The NDA was submitted on April 21, 2014 and is supported by data from a large clinical program...

2014-06-11 16:27:28

ResolveHerpes is Designed to Boost the Body's Immune System and Allow it to Clear Out the Herpes Viruses HSV-1 and HSV-2 LOS ANGELES, June 11, 2014 /PRNewswire-iReach/ -- Resolve Herpes, a company that offers all-natural mineral formulations, has just announced the launch of a new and effective herpes treatment. Called ResolveHerpes, the product is designed to help boost the body's immune system, which in turn can help it naturally clear out the herpes viruses HSV-1 and HSV-2. Photo...

2014-06-09 16:25:29

EMERYVILLE, Calif., June 9, 2014 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), today announced that the United States Patent and Trademark Office (USPTO) issued US Patent No. 8,741,343 entitled "Method Of Administering Amantadine Prior To A Sleep Period." The claims of this patent are directed towards administration, prior to bedtime, of certain formulations of amantadine HCl, including Adamas' lead product ADS-5102 and similar amantadine-based products. "This is the...

2014-06-04 08:34:06

LONDON, June 4, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Hepatitis Drugs and Vaccines: World Market 2013-2023http://www.reportbuyer.com/pharma_healthcare/therapeutic/hepatitis_drugs_vaccines_world_market_2013_2023.html Report DetailsYour guide to sales outlooks and R&D for hepatitis treatmentsWhere are hepatitis medicines going? Visiongain's updated report predicts revenues there from 2013 to 2023. It also explains trends in that business and...

2014-06-02 23:10:38

polyDNA’s May 2014 survey revealed that 14% of elderly respondents wanted to know if a common virus could cause inflammatory bowel disease. polyDNA reviews the literature and recommends taking Gene-Eden-VIR or Novirin. Rochester, NY (PRWEB) June 02, 2014 polyDNA’s latest survey discovered that some older participants wanted to know if a common virus could cause inflammatory bowel disease. The answer is “yes.” The cytomegalovirus (CMV) can cause inflammation of the colon. This is a...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.